Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor

Modification of the recently described leukocyte adherence inhibition (LAI) test was utilized for the evaluation of anti-tumour cell-mediated immunity and the identification of "blocking" factor in 20 patients with prostatic cancer. Evidence of cross-reactivity of the observed anti-tumour immunity with extracts prepared from tumours of the same type and the specificity of "blocking" of the reactions for autologous sensitized lymphocytes and tumour only have similarly been demonstrated employing the LAI test. While the observed cross-reactivity between individual tumours, within each tumour type is in keeping with observations of anti-tumour immunity in patients with other tumours, e.g., colon, breast and melanoma, observations suggestive of a specificity of "blocking" for autologous tumour only is perhaps somewhat unique, of which further studies will be needed to confirm.